NCT04913922View on ClinicalTrials.gov

Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2026

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Azacitidine Injection

s.c. 75 mg/m2 BSA for 7 days

DRUG

Nivolumab

480 mg i.v.

DRUG

Relatlimab

80-160mg i.v.

Trial Locations (1)

81377

RECRUITING

University Hospital, LMU Munich, Munich

All Listed Sponsors
lead

Ludwig-Maximilians - University of Munich

OTHER